{"product_id":"neuro-oncology-volume-27-issue-5-may-2025-by-oxford-university-press","title":"Neuro-Oncology Volume 27 Issue 5 May 2025 by Oxford University Press","description":"\u003ch2 data-section-id=\"1h9cod2\" data-start=\"73\" data-end=\"148\" style=\"text-align: center;\"\u003eSpecialist research and clinical insights for neuroscience professionals\u003c\/h2\u003e\n\u003cp data-start=\"1040\" data-end=\"1090\"\u003e\u003cstrong data-start=\"1040\" data-end=\"1090\"\u003eVery Good Condition – light edge wear visible.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv class=\"wp-block-media-text is-stacked-on-mobile\"\u003e\n\u003cdiv class=\"wp-block-media-text__content\"\u003e\n\u003cp\u003eA Phase 3 trial comparing radiation alone versus radiation with temozolomide for grade II gliomas provides new evidence for combination therapy approaches. The ECOG-ACRIN E3F05 study evaluated outcomes in 172 patients over a median follow-up period of 117 months, offering substantial data on survival benefits and toxicity profiles.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"The Value Junction ","offers":[{"title":"Default Title","offer_id":47789465534676,"sku":"TVJ-020391","price":11.5,"currency_code":"NZD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0721\/3059\/2980\/files\/IMG_7930_5d30b85b-4262-4eab-9833-4c812a7f989f.jpg?v=1776144385","url":"https:\/\/thevaluejunction.co.nz\/products\/neuro-oncology-volume-27-issue-5-may-2025-by-oxford-university-press","provider":"The Value Junction ","version":"1.0","type":"link"}